Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2022-07-20
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Myocardial Ischemia Detection With a Combined Cardiovascular Magnetic Resonance and Biomarker Protocol
NCT05813210
Validation of Different Diagnostic Modalities in the Detection of Cardiac Amyloidosis Among Patients With "Red Flags"
NCT06175858
Echocardiographic Characterization of Cardiac Amyloidosis
NCT05760287
Early Detection of Cardiac Amyloidosis
NCT05010980
Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis
NCT05557162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transthyretin (ATTR) cardiac amyloidosis
Subjects diagnosed with ATTR cardiac amyloidosis will have CMR, TTE, and 6-minute walk
Cardiac magnetic resonance image (CMR)
A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
Transthoracic Echocardiogram (TTE)
An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
Six-minute Walk Test
A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
Light chain amyloidosis (AL) with cardiac involvement
Subjects diagnosed with AL with cardiac involvement will have CMR, TTE, and 6-minute walk
Cardiac magnetic resonance image (CMR)
A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
Transthoracic Echocardiogram (TTE)
An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
Six-minute Walk Test
A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
Light chain amyloidosis (AL) without cardiac involvement
Subjects diagnosed with AL without cardiac involvement will have CMR, TTE, and 6-minute walk
Cardiac magnetic resonance image (CMR)
A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
Transthoracic Echocardiogram (TTE)
An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
Six-minute Walk Test
A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
Healthy Control
Subjects without history of cardiovascular diseases will have CMR, TTE, and 6-minute walk
Cardiac magnetic resonance image (CMR)
A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
Transthoracic Echocardiogram (TTE)
An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
Six-minute Walk Test
A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiac magnetic resonance image (CMR)
A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
Transthoracic Echocardiogram (TTE)
An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
Six-minute Walk Test
A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is able to provide written informed consent and is willing and able to complete study procedures.
* Currently in sinus rhythm by clinical assessment or documented electrocardiographic studies.
* Subject and disease characteristics noted by medical record review:
* Healthy control volunteers must also meet the following criteria: Karnofsky performance scale \> 80%; ECOG status 0 or 1.
* ATTR cardiac amyloidosis based on meeting all the following criteria: Diagnosis of amyloidosis within five years prior to study screening; Documentation of absence of AL, heavy chain disease, multiple myeloma or malignant lymphoproliferative disorders; Transthyretin amyloid deposits in cardiac tissue OR technetium (99mTc) pyrophosphate scintigraphy with grade 2 or 3 cardiac uptake OR Transthyretin amyloid deposits in non-cardiac tissue with echocardiographic evidence of cardiac involvement or an end-diastolic mean wall thickness \>12mm OR Transthyretin amyloid deposits in non-cardiac tissue with CMR diagnostic of amyloidosis
* AL with cardiac involvement based on meeting all the following criteria: Diagnosis of amyloidosis within five years prior to study screening; Histopathologic diagnosis of amyloidosis with AL protein identification; Documented clinical signs or symptoms consistent with heart failure; Cardiac involvement as defined by: Amyloid deposits in cardiac deposits OR Echocardiography with an end-diastolic mean wall thickness \> 12 mm in the absence of other causes OR Elevated NT-proBNP (\>332 ng/L) in the absence of renal failure or atrial fibrillation OR CMR diagnostic of amyloidosis;
* AL without cardiac involvement based on meeting all the following criteria: Diagnosis of amyloidosis within five years prior to study screening; Histopathologic diagnosis of amyloidosis with AL protein identification; No documented clinical signs and symptoms consistent with heart failure from AL; Absence of cardiac involvement as defined by: Echocardiography with an end-diastolic mean wall thickness \< 13 mm if the subject does not have other causes for increased wall thickness AND NT-proBNP \<333 ng/L if the subject does not have renal failure or atrial fibrillation AND No CMR diagnostic of amyloidosis if CMR is available prior to screening.
Exclusion Criteria
* Unable to ambulate for 6 minutes (confirmed at study coordinator visit).
* Unable to maintain in supine position for 30 minutes.
* Unable to maintain breath-holding for 10 seconds (confirmed at study coordinator visit).
* Contraindications for safe CMR scanning (e.g., uncontrolled claustrophobia, cochlear implant, implanted neural stimulator).
* Presence of implantable cardiac pacemaker or defibrillator.
* History of complex congenital heart disease, intracardiac shunt (except for patent foramen ovale), prosthetic valves, prosthesis in the main pulmonary artery or ascending thoracic aorta.
* Significant artifact from prior MRI studies.
* Pregnant or breast-feeding women.
* Weight equal to or greater than 155 kg.
* Maximum body side-to-side or anterior-posterior diameter equal to or greater than 70 cm.
* Documented non-sinus rhythm within 1 week prior to screening.
* History of cardiomyopathy or structural heart disease;
* History of valvular disease of greater than mild severity;
* History of coronary artery disease or coronary heart disease;
* History of cardiac or thoracic surgery.
* History of symptomatic, persistent atrial tachyarrhythmia, ventricular tachyarrhythmia, or bradyarrhythmia;
* Left ventricular hypertrophy or abnormally increased myocardial thickness by prior echocardiography, cardiac computed tomography, or CMR;
* Acute kidney injury, OR chronic renal disease with glomerular filtration rate \< 45 mL/min/1.73m\^2 as per medical record review.
* Uncontrolled hypertension of systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 90 mmHg as per medical record review;
* Taking three or more anti-hypertensive medications;
* Type 1 diabetes, OR uncontrolled type 2 diabetes mellitus of hemoglobin A1c greater than 8, as per medical record review;
* Taking three or more diabetic medications;
* History of confirmed stroke or transient ischemic attack, as per medical record review;
* Current cigarette smoker;
* History of plasma cell dyscrasia or chronic malignant hematologic diagnosis;
* BMI \> 35 kg/m\^2.
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ian C. Chang
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ian C Chang, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-001098
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.